// App-Quantinova.ai

225 2014 ATVB : Apolipoprotein A-IV Is a ?3 Integrin Ligand and an Endogenous Inhibitor of Platelets: Novel Mechanisms of Prevention and Treatment for Atherothrombosis

Researchers

Presenter

  • Lining Ju

Principal Investigators

  • Jina Song

  • Guangheng Zhu

  • Xi Lei

  • Sean Lang

  • Pingguo Chen

  • Phil Connelly

  • YiMin She

  • Hong Yang

  • Terry Cyr

  • Cheng Zhu

  • John Freedman

  • Patrick Tso

  • Sean Davidson

  • Heyu Ni

  • Adili Reheman

  • Yiming Wang

  • Hailong Zhang

  • Yan Yang

  • Emily C Reddy

Medical Centers

  • St. Michael's Hosp, Toronto, ON, Canada

  • University of Cincinnati, Cincinnati, OH

  • Joseph W Jin, St. Michael's Hosp

  • Ottawa,Canada

  • Guangzhou Univ of Chinese Med, Toronto, ON, Canada

  • Georgia Inst. of Technology, Atlanta, GA

  • Toronto, ON, Canada

  • St. Michaels Hospital

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Atherothrombosis

Biomarkers

  • Apolipoprotein A-4

Drug/Treatment

  • Fibrinogen (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved